A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension

• Sponsor: Theratocular Biotek Co. (Industry)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05456724
• Collaborator: Novotech (Australia) Pty Limited (Industry)
• Enrollment: 50
• Location: 1
• Arms: 2
• Anticipated Duration (Months): 12
• Patients Per Site Per Month: 4.2

Study Details

Study Description

Brief Summary

This is a Phase I/II stage to investigate the safety, tolerability, and ocular hypotensive efficacy of TO-O-1001 in healthy volunteers and patients with Open-Angle Glaucoma or Ocular Hypertension.

The proposed trial consists of 3 study parts to be conducted at Nucleus Network Melbourne.

This study will enroll up to 34 evaluable healthy volunteers in part 1(SAD) and part 2(MD) and 16 evaluable patients with Open-Angle Glaucoma or Ocular Hypertension in part 3(MD).

Condition or Disease	Intervention/Treatment	Phase
Open Angle Glaucoma; Ocular Hypertension	Drug: TO-O-1001; Other: Placebo	Phase 1/Phase 2

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 50 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A 3-Part, First-in-human, Double-Blind, Randomized, and Placebo-Control Study Assessing the Safety, Tolerability, and Efficacy of TO-O-1001 Ophthalmic Solution in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension
• Anticipated Study Start Date: Aug 1, 2022
• Anticipated Primary Completion Date: Mar 31, 2023
• Anticipated Study Completion Date: Jul 31, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: A (TO-O-1001) Drug: TO-O-1001 Dose level: 0.05% and 0.1% Dosage form: ophthalmic solution Route of administration: topical ocular	Drug: TO-O-1001; TO-O-1001 ophthalmic solution in two concentration (0.05% and 0.1%) ocular administration only one drop in one eye
Placebo Comparator: B (Placebo) Dosage form: ophthalmic solution Route of administration: topical ocular	Other: Placebo; The placebo is of same visual appearance and identical formulation as TO-O-1001, except the active component TO-168 ocular administration only one drop in one eye

Outcome Measures

Primary Outcome Measures

1. Safety and tolerability of TO-O-1001 though the incidence of adverse events. [Up to 28 days]

   Number of participants with treatment-emergent adverse events (AEs).

2. Evaluate the ocular hypotensive efficacy of TO-O-1001 through Goldmann Applanation Tonometry. [Up to 28 days]

   The primary efficacy outcome is mean IOP.

Secondary Outcome Measures

1. Pharmacokinetics of TO-O-1001. Blood samples obtained to evaluate the systemic exposure. [Up to 8 days]

   Parameter: Area Under the Curve (AUC)

2. Pharmacokinetics of TO-O-1001. Blood samples obtained to evaluate the systemic exposure. [Up to 8 days]

   Parameter: Maximum Concentration

3. Pharmacokinetics of TO-O-1001. Blood samples obtained to evaluate the systemic exposure. [Up to 8 days]

   Parameter: Maximum observed concentration (Cmax in first and last dose)

4. Pharmacokinetics of TO-O-1001. Blood samples obtained to evaluate the systemic exposure. [Up to 8 days]

   Parameter: Area under the concentration-time curve (AUC0-t and AUC0-inf in first and last dose)

5. Pharmacokinetics of TO-O-1001. Blood samples obtained to evaluate the systemic exposure. [Up to 8 days]

   Parameter: Time of observed Cmax

6. Pharmacokinetics of TO-O-1001. Blood samples obtained to evaluate the systemic exposure. [Up to 8 days]

   Parameter: Terminal elimination half-life and elimination constant in first and last dose

7. Best Corrected Visual Acuity (BCVA) of TO-O-1001. [Up to 28 days]

   Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

8. Safety and tolerability of TO-O-1001 through the incidence, severity and causality of serious adverse events (SAEs). [Up to 28 days]

   Number of participants with treatment-emergent serious adverse events.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 59 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

For Healthy Subjects (Parts 1 & 2)

1. 18 - 59-year-old healthy male or female subjects who are non-lactating and non-pregnant.

2. BMI 18.0~32.0(kg/m2) and body weight more than 45kg.

3. Intraocular pressure between 10 - 21 mm Hg (inclusive) in each eye.

4. Best-corrected visual acuity (BCVA) in each eye of 20/40 ETRDS or better.

5. The informed consent form has been read, signed and dated by the subjects.

6. Able to communicate well with the investigator and comply with the requirements of the study.

For Patients (Part 3)

1. Must be 18 years of age or older.

2. Diagnosis of primary open angle glaucoma (POAG) or ocular hypertension (OHT).

3. Unmedicated or after washout intraocular pressure (IOP) >20 mmHg and < 30 mmHg in study eye at T0 (T0 = 08:00AM~10:00 AM) of the first qualification visit (Day 1).

4. Best-corrected visual acuity (BCVA) equivalent to 20/200 ETRDS or better.

5. The informed consent form has been read, signed and dated by the subjects.

6. Able to communicate well with the investigator and comply with the requirements of the study

Exclusion Criteria:

For Healthy Subjects (Parts 1 & 2)

1. Subjects has chronic or acute ophthalmic disease including glaucoma, macular degeneration, and clinically significant cataract (primary or secondary).

2. Subjects has previous glaucoma intraocular surgery or glaucoma laser procedures within 3 years.

3. Subjects has refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.) within 5 years.

4. Subjects has ocular trauma within the past 6 months, or ocular surgery or laser treatment within the past three months (e.g., laser treatment for glaucoma or retina).

For Patients (Part 3)

1. Closed or very narrow angles (Grade 0-1) or those the investigator judges as occludable and/or with evidence of peripheral anterior synechiae (PAS) ≥ 180 degrees by gonioscopy within 6 months prior to Screening Visit in either eye. (Patent laser iridotomy with Grade 1-2 angles is acceptable in either eye, providing the PAS criteria are still met).

2. Previous glaucoma intraocular surgery in either eye. Prior laser trabeculoplasty (ALT or SLT) in either eye is allowed if performed more than 6 months prior to Screening Visit.

3. Any non-glaucoma intraocular surgery within 3 months prior to Screening Visit in either eye.

4. Participation in a clinical study with use of any investigational drug or treatment within 28 days prior to Baseline (Day 1).

5. Clinically significant abnormalities in: laboratory tests, physical examination, vital signs and/or ECG at Screening Visit. If in the investigator's judgment a subjects with clinically significant abnormalities is appropriate for enrollment in the study, a discussion between the investigator and the Medical Monitor must occur and be documented prior to enrollment of this subjects in the study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Nucleus Network Melbourne	Melbourne	Victoria	Australia	3004

Sponsors and Collaborators

• Theratocular Biotek Co.
• Novotech (Australia) Pty Limited

Investigators

• Principal Investigator: Sam Francis, Nucleus Network Melbourne

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Theratocular Biotek Co.
• ClinicalTrials.gov Identifier: NCT05456724
• Other Study ID Numbers: TO-01C101
• First Posted: Jul 13, 2022
• Last Update Posted: Jul 13, 2022
• Last Verified: Jul 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension; Hypertension

Study Results

No Results Posted as of Jul 13, 2022